Literature DB >> 20720487

Innate immunity, allergy and atopic dermatitis.

Margarete Niebuhr1, Thomas Werfel.   

Abstract

PURPOSE OF REVIEW: We review here the recent discoveries in innate immunity that shed light on the pathophysiology of atopic dermatitis. RECENT
FINDINGS: The mechanisms that promote the enhanced susceptibility to cutaneous infections in atopic dermatitis are complex interactions among several factors. They include skin barrier dysfunction, reduced skin lipid content, and abnormalities of the innate immune response. Some of the innate immune defects observed in atopic dermatitis are primary defects, such as epithelial barrier defects and defects in signaling or expression of innate receptors. Others may be secondary to the effects of the adaptive immune response. For example, deficiencies in antimicrobial peptides may be due to the overexpression of T helper 2 cytokines such as interleukin-4 and interleukin-13. However, how all components interact with each other remains to be fully investigated.
SUMMARY: To break this vicious circle, a multiprolonged approach directed at healing or protecting the skin barrier and addressing the immune dysregulation is necessary to improve and control the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20720487     DOI: 10.1097/ACI.0b013e32833e3163

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  10 in total

1.  Interleukin-13 interferes with activation-induced t-cell apoptosis by repressing p53 expression.

Authors:  Li Yang; Ling-Zhi Xu; Zhi-Qiang Liu; Gui Yang; Xiao-Rui Geng; Li-Hua Mo; Zhi-Gang Liu; Peng-Yuan Zheng; Ping-Chang Yang
Journal:  Cell Mol Immunol       Date:  2015-07-20       Impact factor: 11.530

Review 2.  [Specific immunotherapy and atopic dermatitis. What is new?].

Authors:  N Novak; T Werfel
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

3.  Oxazolone and ethanol induce colitis in non-obese diabetic-severe combined immunodeficiency interleukin-2Rγ(null) mice engrafted with human peripheral blood mononuclear cells.

Authors:  T Nolte; M Zadeh-Khorasani; O Safarov; F Rueff; V Gülberg; N Herbach; A Wollenberg; T Mueller; M Siebeck; E Wolf; R Gropp
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

4.  Impaired Toll-like receptor 2-mediated Th1 and Th17/22 cytokines secretion in human peripheral blood mononuclear cells from patients with atopic dermatitis.

Authors:  Yangyang Yu; Yarui Zhang; Jie Zhang; Xia Dou; Hong Yang; Yong Shao; Kepeng Wang; Bo Yu; Wei Zhang; Hang Yung Alaster Lau
Journal:  J Transl Med       Date:  2015-12-18       Impact factor: 5.531

5.  Effects of Cymbidium Root Ethanol Extract on Atopic Dermatitis.

Authors:  Wan-Joong Kim; Hae-Sim Cha; Myung-Hun Lee; Sun-Young Kim; Seo Ho Kim; Tack-Joong Kim
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-11       Impact factor: 2.629

6.  A Real-Life Based Evaluation of the Effectiveness of Antibacterial Fabrics in Treating Atopic Dermatitis.

Authors:  Dirk Höfer
Journal:  Dermatol Res Pract       Date:  2018-11-19

Review 7.  Exploring the Role of Staphylococcus Aureus Toxins in Atopic Dermatitis.

Authors:  Fabio Seiti Yamada Yoshikawa; Josenilson Feitosa de Lima; Maria Notomi Sato; Yasmin Álefe Leuzzi Ramos; Valeria Aoki; Raquel Leao Orfali
Journal:  Toxins (Basel)       Date:  2019-06-05       Impact factor: 4.546

8.  Vitamin D Receptor Gene Polymorphisms and Risk of Atopic Dermatitis in Chinese Han Population.

Authors:  Yunchao Ou; Xiaoli Jiang; Huiwen Guan
Journal:  Int J Gen Med       Date:  2021-09-07

Review 9.  Role of macrophages in the pathogenesis of atopic dermatitis.

Authors:  Sadaf Kasraie; Thomas Werfel
Journal:  Mediators Inflamm       Date:  2013-03-04       Impact factor: 4.711

10.  Solanum tuberosum L. cv Hongyoung extract inhibits 2,4‑dinitrochlorobenzene‑induced atopic dermatitis in NC/Nga mice.

Authors:  Myung Ah Kang; Se-Young Choung
Journal:  Mol Med Rep       Date:  2016-08-08       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.